Do the SIPPET study results apply to the patients I treat?

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F17%3A00066301" target="_blank" >RIV/65269705:_____/17:00066301 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/17:00096126
Result on the web
<a href="https://onlinelibrary.wiley.com/doi/abs/10.1111/hae.13133" target="_blank" >https://onlinelibrary.wiley.com/doi/abs/10.1111/hae.13133</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/hae.13133" target="_blank" >10.1111/hae.13133</a>

Result language
angličtina
Original language name
Do the SIPPET study results apply to the patients I treat?
Original language description
We thank the investigators and participants of SIPPET (Survey of Inhibitors in Plasma-Products Exposed Toddlers) study 1 for their invaluable commitment to provide evidence for the improvement of care for haemophilia. While we do not question that in SIPPET, plasma-derived concentrates were associated with lower risk of developing inhibitors; we regret to see that incomplete reporting of the study precludes the adoption of study results in clinical practice. After establishing that the study results are valid (i.e. the two study arms were balanced, and results are unconfounded), each doctor has to evaluate the applicability of the study results, which includes similarity of the study population and treatment to those the doctor cares for.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)